Recombinant Human CD22 Protein (Asp20-Arg687), C-hFc and Avi-tagged, Biotinylated
Product Description
Cat
IMP-10270
Official Symbol
CD22
Product Overview
Biotinylated recombinant human Siglec-2/CD22 protein (Asp20-Arg687) with a Human IgG1 (Pro100-Lys330) Fc tag and Avi-tag at C-terminus was expressed in Chinese Hamster Ovary cell line.
Description
Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome.
Expression System
CHO
Species
Human
Tag
C-hFc and Avi
Predicted N Terminal
Asp20
Form
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Conjugate
Biotinylated
Molecular Mass
Predicted Molecular Mass: 104 kDa
SDS-PAGE: 120-140 kDa, under reducing conditions.
Protein length
Asp20-Arg687
Bio-activity
Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. The ED50 for this effect is 0.1-0.9 μg/mL. Measured by its binding ability in a functional ELISA. When Human Siglec-2/CD22 (Epratuzumab) Antibody is immobilized at 0.2 μg/mL (100 μL/well), Biotinylated Recombinant Human Siglec-2/CD22 Fc Chimera Avi-tag binds with an ED50 of 1.5-18 ng/mL.
Endotoxin
<0.10 EU/μg of the protein by the LAL method.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.
Notes
Disulfide-linked homodimer, biotinylated via Avi-tag
Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitution
Reconstitute at 500 μg/mL in PBS.
SDS-PAGE
SDS-PAGE

Bioactivity-ELISA 1
Bioactivity

Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. The ED50 for this effect is 0.1-0.9 μg/mL. Measured by its binding ability in a functional ELISA. When Human Siglec-2/CD22 (Epratuzumab) Antibody is immobilized at 0.2 μg/mL (100 μL/well), Biotinylated Recombinant Human Siglec-2/CD22 Fc Chimera Avi-tag binds with an ED50 of 1.5-18 ng/mL.

Data Sheet MSDS
Datasheet MSDS
For research or industrial raw materials, not for personal medical use!

Online Inquiry
Contact Info
Copyright © Creative BioMart. All rights reserved.